1. PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety.
- Author
-
Zhang J, Li W, Qi Y, Wang G, Li L, Jin Z, Tian J, and Du Y
- Subjects
- Animals, Mice, Cell Line, Tumor, B7-H1 Antigen, Immunotherapy, Metal-Organic Frameworks, Photochemotherapy, Nanoparticles therapeutic use, Neoplasms drug therapy
- Abstract
Immune checkpoint blockade has become a paradigm-shifting treatment modality to combat cancer, while conventional administration of immune checkpoint inhibitors, such as anti-PD-L1 antibody (α-PD-L1), often shows unsatisfactory immune responses and lead to severe immune-related adverse effects (irAEs). Herein, we develop a PD-L1 aptamer-based spherical nucleic acids (SNAs), which consists of oxaliplatin (OXA) encapsulated in a metal-organic framework nanoparticle core and a dense shell of aptPD-L1 (denoted as M@O-A). Upon light irradiation, this nanosystem enables concurrent photodynamic therapy (PDT), chemotherapy, and enhanced immunotherapy in one shot to inhibit both primary colorectal tumors and untreated distant tumors in mice. Notably, M@O-A shows scarcely any systemic immunotoxicity in a clinical irAEs-mimic transgenic mouse model. Collectively, this study presents a novel strategy for priming robust photo-immunotherapy against cancer with enhanced safety., (© 2022 Wiley-VCH GmbH.)
- Published
- 2023
- Full Text
- View/download PDF